← Back to headlines
Regenxbio Outlines Accelerated Approval Path for RGX-202
Regenxbio has outlined a potential accelerated approval pathway for its gene therapy RGX-202 in 2027, following positive results from its pivotal Phase III primary endpoint.
15 May, 00:32 — 15 May, 00:32
Sources
Showing 1 of 1 sources
